Current Report Filing (8-k)
November 07 2019 - 4:08PM
Edgar (US Regulatory)
false0001628738
0001628738
2019-11-07
2019-11-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
———————
FORM 8-K
———————
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 7, 2019
———————
Audentes Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
———————
|
|
|
|
|
|
|
|
Delaware
|
001-37833
|
46-1606174
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
600 California Street, 17th Floor
|
San Francisco
|
California
|
94108
|
|
(Address of Principal Executive Offices)
|
|
|
(Zip Code)
|
(415) 818-1001
Registrant's Phone Number, including Area Code
Not Applicable
(Former Name of Former Address, if Changed Since Last Report)
——————
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
Trading Symbol
|
Name of exchange on which registered
|
|
Common Stock, par value $0.00001 per share
|
BOLD
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 7, 2019, Audentes Therapeutics, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2019. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.
The information furnished with Item 2.02 of this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
|
|
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
|
|
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
Audentes Therapeutics, Inc.
|
|
Date: November 7, 2019
|
By:
|
/s/ Mark Meltz
|
|
|
|
Mark Meltz
|
|
|
|
Senior Vice President, General Counsel
|
|
|
|
|
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boundless Bio (NASDAQ:BOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024
